Investor Relations

Investor Relations

NASDAQCMMB
YearTrailing 12-MonthsCalendar Year 2026Calendar Year 2025Calendar Year 2024Calendar Year 2023Calendar Year 2022Calendar Year 2021Calendar Year 2020Calendar Year 2019Calendar Year 2018Calendar Year 2013Calendar Year 2012Calendar Year 2011
ViewAll FilingsAnnual FilingsQuarterly FilingsCurrent FilingsRegistration StatementsSection 16Mergers & AcquisitionsProxy & Information StatementsOther
FormDescriptionDateFormat
6-KReport of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange ActNov 18, 2024Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in HTML.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in DOC file.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in PDF file.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in XLS file.
6-KReport of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange ActNov 14, 2024Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in HTML.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in DOC file.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in PDF file.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in XLS file.
6-KReport of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange ActOct 11, 2024Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in HTML.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in DOC file.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in PDF file.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in XLS file.
6-KReport of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange ActAug 21, 2024Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in HTML.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in DOC file.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in PDF file.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in XLS file.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in XBLR Viewer.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in XBLR file.
6-KReport of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange ActJul 25, 2024Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in HTML.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in DOC file.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in PDF file.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in XLS file.
6-KReport of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange ActJun 12, 2024Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in HTML.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in DOC file.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in PDF file.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in XLS file.
6-KReport of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange ActMay 9, 2024Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in HTML.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in DOC file.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in PDF file.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in XLS file.
6-KReport of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange ActMay 8, 2024Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in HTML.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in DOC file.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in PDF file.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in XLS file.
6-KReport of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange ActMay 3, 2024Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in HTML.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in DOC file.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in PDF file.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in XLS file.
6-KReport of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange ActMar 7, 2024Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in HTML.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in DOC file.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in PDF file.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in XLS file.
6-KReport of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange ActJan 3, 2024Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in HTML.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in DOC file.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in PDF file.Open Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act in XLS file.
About
Chemomab Therapeutics Ltd.

Chemomab is developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed nebokitug (CM-101), a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying potential. In clinical and preclinical studies, nebokitug has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from five clinical trials of nebokitug. Based on positive data from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC), the company is preparing for potential initiation of a nebokitug Phase 3 trial in PSC. Nebokitug has received FDA and EMA Orphan Drug and FDA Fast Track designations for the treatment of PSC. Chemomab’s nebokitug program for the treatment of systemic sclerosis has an open U.S. IND.

Join our mission.
Collaborate with us.

Collaborate with us.

We are actively seeking strategic collaborations and licensing opportunities that align with our therapeutic areas of focus.

To explore partnership opportunities, please contact us.

Quick
Links

© Copyright 2025 Chemomab Therapeutics Ltd. All rights reserved. Privacy Policy. Terms of Use. Cookie policy.

Site Design by Michael Kulwiec DesignLab.

Site Design by Michael Kulwiec DesignLab.